Pioneering Pain Management: High-Frequency Electrical Stimulation Devices

By HEOR Staff Writer

October 27, 2023

High-frequency electrical stimulation devices

The Current Opioid Crisis and the Treatment of Post-Caesarean Pain

Systemic opioids are the medication that is utilised the most frequently, despite the fact that pain management following a caesarean delivery is a complicated issue. Having said that, this method is not without its flaws. The overprescription of opioids is a key cause, and it is estimated that 1.2 million of the caesarean births performed annually in the United States result in the disposal of 12 million unneeded tablets. There is a high likelihood that these unused tablets will be abused, which will contribute to the continuing opioid problem.

 

A Novel Technique for the Management of Pain

A recent study found that devices that use high-frequency electrical stimulation could be an effective solution to the problem. According to the findings of the study, women who had caesarean deliveries followed by transcutaneous treatment using a high-frequency electrical stimulation device required around 47 percent less opioid analgesic medication while they were in the hospital. In addition, these individuals reported levels of discomfort that were comparable to those reported by patients who had used a sham device.

High-frequency electrical stimulation devices

This breakthrough has the potential to constitute a key step towards lowering the use of opioids, avoiding overprescribing, and preventing dependence from developing. Because it is estimated that 36,000 to 72,000 people in the United States develop a dependence on opioids each year after having a caesarean delivery, finding effective measures to reduce opioid use continues to be a public health priority.

Reference url

Recent Posts

generative AI diagnosis
Generative AI Diagnosis in Neurology Enhances Non-Specialist Accuracy

By João L. Carapinha

June 5, 2026

Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...
Mirvetuximab ovarian cancer
NICE Guidance on Mirvetuximab Ovarian Cancer Treatment

By HEOR Staff Writer

June 5, 2026

Mirvetuximab ovarian cancer treatment has taken a major step forward after NICE recommended mirvetuximab soravtansine for adults with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three...
Immunotherapy for Liver Cancer
Exploring Immunotherapy for Liver Cancer through the EMERALD-3 Trial

By HEOR Staff Writer

June 5, 2026

Immunotherapy for liver cancer has advanced substantially with the EMERALD-3 Phase III trial, which showed that